Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06077760 · ClinicalTrials.gov registry record · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 868
- Enrollment target
- 20
- Study locations
NCT06077760 is a Phase 3 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 868 participants, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (32% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT06077760, a Phase 3 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 868 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Placebo
- BIOLOGICAL Intismeran autogene
Study Locations (20)
California
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0059) - Los Angeles
- Hoag Memorial Hospital Presbyterian ( Site 4042) - Newport Beach
- Hoag Memorial Hospital Presbyterian ( Site 4048) - Newport Beach
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0074) - Orange
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0030) - Orange
Florida
- Mayo Clinic Florida ( Site 4043) - Jacksonville
- Miami Cancer Institute at Baptist Health, Inc. ( Site 4047) - Miami
- Mid Florida Hematology and Oncology Center ( Site 0014) - Orange City
- AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0013) - Orlando
- Moffitt Cancer Center ( Site 0078) - Tampa
Arizona
- The University of Arizona Cancer Center - North Campus ( Site 0071) - Tucson
- YUMA REGIONAL MEDICAL CENTER CANCER CENTER ( Site 0020) - Yuma
Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0012) - Marietta
- Southeastern Regional Medical Center ( Site 0098) - Newnan
Alaska
- Alaska Oncology and Hematology ( Site 0039) - Anchorage
Colorado
- UCHealth Memorial Hospital-Heme Onc ( Site 0052) - Colorado Springs
Idaho
- Beacon Cancer Care ( Site 0044) - Post Falls
Illinois
- Illinois Cancer Care ( Site 7003) - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 868 participants |
| Start Date | 2023-12-06 |
| Est. Completion | 2035-12-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06077760
The ClinicalTrials.gov registry entry for NCT06077760 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 868 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (32% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT06077760 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06077760 about?
NCT06077760 is a clinical study titled "A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)". The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The primary hypothesis is that in...
What is the current status of trial NCT06077760?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 868 participants. The study started on 2023-12-06. Estimated completion is 2035-12-21.
What conditions does trial NCT06077760 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06077760?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Placebo (OTHER), Intismeran autogene (BIOLOGICAL).
Who is sponsoring clinical trial NCT06077760?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06077760 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.